[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"amphetamine-use-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:amphetamine-use-disorders":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100589888","effects-of-repetitive-transcranial-magnetic-stimulations-in-patients-with-amphetamine-use-disorders-100589888",false,"NCT06960265","Effects of Repetitive Transcranial Magnetic Stimulations in Patients With Amphetamine Use Disorders","A Pilot Study for the Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Amphetamine Use Disorders: Clinical Outcomes, Near InfraRed Spectroscopy, and Biomarkers","Inclusion Criteria:\n\n* Age ≥20 years.\n* Meeting DSM-5 criteria for substance use disorder made by a specialist in addiction psychiatry.\n* Fluency in Chinese.\n* Willingness and ability to comply with study requirements.\n* Good physical health determined by complete physical examination, and laboratory tests.\n* Patient or a reliable caregiver can be expected to ensure acceptable compliance and visit attendance for the duration of the study.\n* Trained psychiatrists will assess eligible patients using the structured clinical interview for the Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) to determine the presence of any psychotic disorder.\n\nExclusion Criteria:\n\n* Evidence of an uncontrolled and\u002For clinically significant medical condition, e.g., cardiac, hepatic and renal failure that would compromise patient safety or preclude study participation.\n* Premorbid mental retardation.\n* Other major Axis-I Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) diagnoses other than substance use disorder.\n* Pregnancy or nursing.\n* History of seizures or epilepsy.\n* History of neurological diseases or traumatic brain injury.\n* Suicidal attempts or risks during screening or study period.\n* Presence of prosthesis devices, e.g. pace-makers, cochlear prosthesis, neuro- stimulators, magnetic cochlear prosthesis, intraocular metallic fragments.","ALL","20 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","Amphetamine Use Disorder (AUD) is a major public health issue in Taiwan, where it is the most commonly abused illegal drug. There are currently no effective approved medications to treat it, which makes finding new treatment options urgent. Repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation method, has shown promise in reducing cravings and drug use in people with addiction, but its effects on AUD are not well studied.\n\nTo explore this, the investigators plan to conduct a double-blind, sham-controlled study with 20 people diagnosed with AUD. Half will receive real rTMS treatment, and half will receive a placebo-like sham treatment. The treatment targets a specific brain area (the left dorsolateral prefrontal cortex) and will be given 10 times over two weeks.\n\nThe investigators will assess the effectiveness of rTMS by tracking drug cravings, urine test results, and side effects with follow-up over 12 weeks. The investigators also include brain imaging using near-infrared spectroscopy (NIRS) after the treatment.\n\nThe study aims to better understand how rTMS might help reduce amphetamine cravings and improve outcomes, potentially leading to new treatment options for AUD.",[26,27,28,29,30,31,32],"Amphetamine Use Disorders","Amphetamine Use Disorder","Amphetamine Dependence","Amphetamine Abuse","NIRS","rTMS","rTMS Stimulation",[34,35,30],"amphetamine","rtms","NOT_YET_RECRUITING","2025-04-28",{"date":39,"type":40},"2025-05-07","ACTUAL",{"date":42,"type":20},"2025-05-15",{"date":44,"type":20},"2025-12-31",{"name":46,"class":47},"TsaoTun Psychiatric Center, Department of Health, Taiwan","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":48},"100551219","closed-loop-ctbs-for-the-core-clinical-features-of-methamphetamine-use-disorder-100551219","NCT06457243","Closed-loop cTBS for the Core Clinical Features of Methamphetamine Use Disorder","Closed-loop Neuromodulation Based on Individualised EEG Biomarkers of Methamphetamine Use Disorder","Inclusion Criteria:\n\n* Individuals aged between 18 and 60 years, irrespective of gender, having completed a minimum of 9 years of education and capable of effectively cooperating in questionnaire evaluations.\n* Meet the diagnostic criteria set forth by the DSM-V concerning the amphetamine-type substance addiction.\n* A history of utilizing amphetamine-type substances for a duration not less than one year, with a frequency of use being at least once per week.\n* Consent to actively cooperate in the completion of subsequent follow-up assessments.\n\nExclusion Criteria:\n\n* Severe cognitive functional impairments manifested through a history of head trauma, cerebrovascular diseases, epilepsy, etc., or usage of cognitive enhancement drugs in the past 6 months; an intellectual disability with an IQ score less than 70.\n* A diagnosis of schizophrenia or other severe mental illnesses as per the DSM-5 criteria.\n* Abuse or dependence on other psychoactive substances (excluding nicotine) within the past 5 years.\n* Severe organic diseases that might compromise study participation.\n* Contraindications to cTBS, such as a history of epileptic seizures or the presence of metallic implants in proximity to the head.","18 Years","60 Years",{"count":59,"type":20},30,[23],"Using specific EEG biomarkers in methamphetamine-dependent individuals, this study systematically probes closed-loop continuous Theta-burst Stimulation (cTBS) based on brain states, assessing dosage, neurologic and behavioral effects, while comparing its efficacy with traditional open-loop cTBS methods.",[26],[64,65,66,67],"individualized therapy","closed-loop","Amphetamine-type stimulants","cTBS","RECRUITING","2024-06-10",{"date":71,"type":40},"2024-06-13",{"date":73,"type":20},"2024-08",{"date":75,"type":20},"2025-08",{"name":77,"class":47},"Shanghai Mental Health Center"]